Merck Serono
Rebif approved for early use in MS
January 26, 2012Sales and Marketing MS, Merck KGaA, Merck Serono, Rebif
The European Commission has approved an indication for multiple sclerosis treatment Rebif that treats early signs of the condition.This EC …
Merck Serono returns Parkinson’s drug rights to Newron
October 24, 2011Research and Development, Sales and Marketing Merck Serono, Newron
Merck Serono has returned the rights to the Parkinson’s disease drug safinamide back to Newron. The decision comes after the …
Merck licences new MS drug
September 19, 2011Research and Development Cladribine, Merck KGaA, Merck Serono, PI-2301
Merck KGaA has in-licensed a new multiple sclerosis drug and aims to start it in phase II studies later this …
Merck Serono signs neurodegenerative collaboration
June 9, 2011Research and Development Affectis Pharmaceuticals, Merck Serono
Merck Serono has struck a deal with biotech firm Affectis Pharmaceuticals to develop oral neurodegeneration compounds. The companies will commercialise …
Erbitux meets gold standard in rectal cancer
June 7, 2011Research and Development, Sales and Marketing Erbitux, Merck Serono, rectal cancer
Studies of Merck Serono’s Erbitux in rectal cancer have shown improved overall survival, a gold standard measure in oncology trials. …
Merck KGaA sales soar
February 21, 2011Sales and Marketing 2010 pharma results, Cladribine, Merck KGaA, Merck Serono, Movectro
Merck KGaA’s sales jumped last year by nearly a fifth as recent acquisitions and strong growth on core products set …
Digital Pharma: Merck Serono sets up MS social network
February 18, 2011Medical Communications Digital Pharma blog, MS, Merck Serono, Movectro, Rebif, multiple sclerosis, social networking
Merck Serono has set up an international social network for multiple sclerosis patients, saying today’s pharma companies should go beyond …
Merck Serono halts Movectro European licence application
February 18, 2011Medical Communications, Sales and Marketing Cladribine, MS, Merck KGaA, Merck Serono, Movectro, fingolimod, gilenya, multiple sclerosis
Merck Serono has withdrawn its European licence application for multiple sclerosis drug Movectro. Movectro (cladribine) is a new oral treatment …
Digital Pharma: Merck Serono launches campaign for cancer carers
February 4, 2011Medical Communications Cancer, Digital Pharma blog, Merck Serono, disease awareness campaigns, lung cancer
Merck Serono has launched an educational lung cancer website for the ‘people behind the patients’ in Europe. Unveiled to coincide …
Merck Serono and Domain to co-develop Parkinson’s drugs
January 18, 2011Research and Development Domain Therapeutics, Merck KGaA, Merck Serono, PAM, Parkinson's disease, Parkinson’s disease, Positive Allosteric Modulator, mGluR4, metabotropic glutamate receptor 4
Merck Serono is to work with French biotech company Domain Therapeutics to develop a new treatment for Parkinson’s disease and …
Sanofi and Merck Serono to collaborate in oncology
December 17, 2010Research and Development Cancer, MSC1936369B, Merck Serono, SAR245408, SAR245409, Sanofi, Sanofi-Aventis
Sanofi-Aventis and Merck Serono are to join forces to study three new cancer drug candidates. The collaboration will see the companies …
Merck KGaA appoints new head of pharma
December 17, 2010Manufacturing and Production, Research and Development, Sales and Marketing Elmar Schnee, Merck KGaA, Merck Serono, Stefan Oschmann, appoinment, manufacturing and production, research and development, sales and marketing
Merck KGaA has appointed Stefan Oschmann head of its pharmaceuticals division Merck Serono. He takes office on 1 January 2011 …
Trial failure for Merck Serono’s Parkinson’s candidate
November 8, 2010Research and Development Merck Serono, Newron Pharmaceuticals, Parkinson's disease, dopamine agonists, levodopa, safinamide
Merck Serono’s new alpha-aminoamide safinamide has failed to reach its primary endpoint in a study with Parkinson’s disease patients. Merck …
Merck Serono eyes ‘Nanobody’ potential in rheumatology
October 14, 2010Research and Development Ablynx, Merck Serono
Merck Serono has expanded its research with Ablynx and will co-develop ‘Nanobodies’ from the Belgian biotech against an inflammatory disease …
Merck will appeal EMA’s Movectro decision
October 12, 2010Sales and Marketing CHMP, EMA, Merck KGaA, Merck Serono, Movectro
Merck KGaA is poised to appeal the EMA’s decision on its MS treatment Movectro after the regulator rejected the drug …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
